Skip to content

Effect of Yastimadhu bhavitha Kutala gulika in Eka Kushta

Clinical study to assess the efficacy of Vamana with Yastimadhu bhavitha Kutaja gulika in Eka kushta(psoriasis)

Status
Recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2017/08/009533
Enrollment
30
Registered
2017-08-29
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Psoriasis

Interventions

Intervention1: Yastimadhu Bhavitha Kutaja gulika: Yastimadhu Bhavitha Kutaja gulika Dose 12 gms Frequency once Oral route of administration Duration of therapy one day given for Vamana karma Contro

Sponsors

Sri Dharmasthala Manjunatheshwara College of Ayurveda and Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Between the age of 18 to 70 years Patient who are fit for vamana Patients who are willing to give consent

Exclusion criteria

Exclusion criteria: Patients with cardiac diseases

Design outcomes

Primary

MeasureTime frame
To evaluate the efficacy of Yastimadhu bhavitha Kutaja Gulika for vamana in Eka kushta(Psoriasis) To evaluate the efficacy of Yastimadhu bhavitha Kutaja Gulika as vamaka yoga Route of administration oral frequency 1 time during vamana karma duration of the study 14days Out come will be accessed on 8th day after vamana karmaTimepoint: To evaluate the efficacy of Yastimadhu bhavitha Kutaja Gulika for vamana in Eka kushta (Psoriasis) To evaluate the efficacy of Yastimadhu bhavitha Kutaja Gulika as vamaka yoga

Secondary

MeasureTime frame
Improve in the overall health of the patient Reduced complaints of psoriasisTimepoint: 7 days

Countries

India

Contacts

Public ContactDr Ashvini Kumar M

Sri Dharmasthala Manjunatheshwara college of Ayurveda and Hospital

ashvinipanchakarma@gmail.com9448705660

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026